BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 16428499)

  • 1. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrimidine dehydrogenase deficiency in an Indian population.
    Saif MW; Mattison L; Carollo T; Ezzeldin H; Diasio RB
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):396-401. PubMed ID: 16421754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.
    Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
    Drug Metab Dispos; 2005 Mar; 33(3):381-7. PubMed ID: 15616154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
    Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
    Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.
    Ito S; Kawamura T; Inada M; Inoue Y; Hirao Y; Koga T; Kunizaki J; Shimizu T; Sato H
    Br J Clin Pharmacol; 2005 Dec; 60(6):584-93. PubMed ID: 16305582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
    Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
    Pharmacogenet Genomics; 2008 Jan; 18(1):25-35. PubMed ID: 18216719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs.
    Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1205-9. PubMed ID: 17065092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
    Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
    Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
    van Staveren MC; Opdam F; Guchelaar HJ; van Kuilenburg AB; Maring JG; Gelderblom H
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):47-52. PubMed ID: 25957957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
    Mattison LK; Ezzeldin H; Carpenter M; Modak A; Johnson MR; Diasio RB
    Clin Cancer Res; 2004 Apr; 10(8):2652-8. PubMed ID: 15102667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
    Cunha-Junior GF; De Marco L; Bastos-Rodrigues L; Bolina MB; Martins FL; Pianetti GA; Cesar IC; Coelho LG
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1273-82. PubMed ID: 24101147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
    Yan J; Tyring SK; McCrary MM; Lee PC; Haworth S; Raymond R; Olsen SJ; Diasio RB
    Clin Pharmacol Ther; 1997 May; 61(5):563-73. PubMed ID: 9164418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z; Zhang R; Diasio RB
    Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
    Nakamura A; Kikuchi K; Ohishi T; Masuike T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.